Annexon, Inc. ANNX
At closeNov 3, 2026, 4:51 PM EST
After hours · Nov 3, 4:51 PM ET
- YTD
- -16.53%
- 1 year
- +32.18%
- Market cap
- 794.34M
- EPS (ttm)
- -1.13
- Shares out
- 160.47M
- Forward P/E
- -6.48
- YTD return
- -16.53%
- 1-year return
- +32.18%
- Volume
- 4.28M
- Avg volume
- 3.13M
- Open
- 3.98
- Previous close
- 3.94
- Day's range
- 3.94 – 4.23
- 52-week range
- 2.54 – 7.18
- Beta
- 1.15
- Analysts
- Strong Buy
- Price target
- 13.71 (+227.3%)
- Earnings date
- Nov 9, 2026
1M -0.01 (-0.24%)
Key statistics
- Enterprise value
- 819.71M
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 4.38
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- -104.48M
- Total cash
- 238.34M
- Total debt
- 26.20M
- Return on equity
- -81.90%
- Short % of float
- 13.45%
- 50-day average
- 5.52
- 200-day average
- 4.10
Analyst view
Consensus: strong buy
- Target (low)
- 8.00
- Target (mean)
- 13.71
- Target (high)
- 27.00
- Strong buy2
- Buy7
- Hold0
- Sell0
- Strong sell0
Next earnings
Nov 9, 2026
Expected Nov 9, 2026. Consensus EPS estimate -0.30268.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 9, 2026 | Sep 30, 2026 | -0.26 | — | — | — |
| Aug 12, 2026 | Jun 30, 2026 | -0.23884 | -0.28 | -0.04 | -17.23% |
| May 7, 2026 | Mar 31, 2026 | -0.30 | -0.23 | +0.07 | +23.33% |
| Mar 30, 2026 | Dec 31, 2025 | -0.32 | -0.28 | +0.04 | +12.50% |
| Nov 10, 2025 | Sep 30, 2025 | -0.34 | -0.37 | -0.03 | -8.82% |
| Aug 14, 2025 | Jun 30, 2025 | -0.36 | -0.34 | +0.02 | +5.56% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Mar 20, 2026 | Chardan Capital | main | Buy | Buy |
| Dec 23, 2025 | Chardan Capital | init | — | Buy |
| Dec 2, 2025 | Clear Street | init | — | Buy |
| Nov 19, 2025 | Wells Fargo | main | Overweight | Overweight |
| Aug 15, 2025 | HC Wainwright & Co. | reit | Buy | Buy |
| May 14, 2025 | HC Wainwright & Co. | main | Buy | Buy |
About Annexon, Inc.
Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. The company provides Tanruprubart, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase 2a clinical trial for the treatment of amyotrophic lateral sclerosis. It is also developing ANX007, an antigen-binding fragment (Fab) that is in Phase 3 program for the treatment of patients with geographic atrophy; and ANX1502, a novel oral small molecule inhibitor, which is in Phase 1 clinical trials for autoimmune indications. In addition, it develops ANX009, a C1q-blocking Fab that is in Phase I clinical trial for treating patients with lupus nephritis. The company was incorporated in 2011 and is headquartered in Brisbane, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- annexonbio.com
News
Annexon To Highlight Phase 3 ARCHER II Clinical Trial Program At Virtual Investor Event 
Annexon to Host Virtual Investor Event on November 3, 2026: Vonaprument for the Treatment of Geographic Atrophy - Highlighting Key Aspects of Phase 3 ARCHER II Trial 
Microsoft To Rally Around 25%? Here Are 10 Top Analyst Forecasts For Monday 
HC Wainwright & Co. Maintains Buy on Annexon, Raises Price Target to $25 
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) 
12 Health Care Stocks Moving In Friday's Pre-Market Session 
JP Morgan Maintains Overweight on Annexon, Raises Price Target to $15 
Annexon: Preserving Patient Function Is The Real Investment Opportunity 
Annexon to Present Patient Baseline Characteristics from Vonaprument Phase 3 ARCHER II Pivotal Trial for Geographic Atrophy at The Retina Society 59th Annual Scientific Meeting 
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
Your note
Sign in to keep a note on ANNX — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| ARTIS DEAN RICHARD PH.D. | Officer | Sale | Mar 1, 2026 | 180,093 |
| CARSON WILLIAM H. | Director | Purchase | Apr 9, 2026 | 70,405 |
| CHOI JUNG E. | Director | Purchase | Nov 30, 2025 | 0 |
| DANANBERG JAMIE | Officer | Sale | Mar 1, 2026 | 123,582 |
| LEW JENNIFER | Chief Financial Officer | Sale | Mar 1, 2026 | 170,700 |
| LOVE DOUGLAS ESQ. | Chief Executive Officer | Sale | Feb 12, 2025 | 351,554 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| FMR, LLC | 6.29% | 10,222,470 | 63.38M | Dec 30, 2025 |
| Redmile Group, LLC | 6.18% | 10,050,644 | 62.31M | Dec 30, 2025 |
| BVF Inc. | 5.62% | 9,128,080 | 56.59M | Dec 30, 2025 |
| Blackrock Inc. | 5.51% | 8,960,434 | 55.55M | Dec 30, 2025 |
| Vanguard Group Inc | 4.77% | 7,753,387 | 48.07M | Dec 30, 2025 |
| Adage Capital Partners GP L.L.C. | 3.38% | 5,500,000 | 34.10M | Dec 30, 2025 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity Select Portfolios-Select Biotechnology Portfolio | 2.91% | 4,733,596 | 29.35M | Feb 27, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 2.65% | 4,314,036 | 26.75M | Dec 30, 2025 |
| iShares Trust-iShares Russell 2000 ETF | 1.49% | 2,422,177 | 15.02M | Feb 27, 2026 |
| SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF | 1.45% | 2,357,790 | 14.62M | Feb 27, 2026 |
| Columbia Acorn Trust-Columbia Acorn Fund | 1.10% | 1,786,958 | 11.08M | Dec 30, 2025 |
| College Retirement Equities Fd.-College Retirement Equities Fd. - Tota | 0.92% | 1,499,900 | 9.30M | Dec 30, 2025 |